Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| STAAR SURGIC | STAA | 10.98% |
| DTS INC | DTSI | 6.89% |
| ANIKA THERAP | ANIK | 6.04% |
| LUMOS NETWOR | LMOS | 5.70% |
| INSTEEL IND | IIIN | 5.28% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
We have reaffirmed our Neutral recommendation on Canadian National Railway (CNI - Analyst Report), reflecting its favorable position to reap benefits from improving demand and pricing trends along with planned investment programs and productivity enhancement measures. However, the current market volatility and competitive pressure are expected to weigh on the stock.
Why the Reiteration?
Montreal, Canada based Canadian National Railway is expected to witness growth across all its business segments in 2013. Merchandize will remain one of the prime revenue contributors, with gains in metals and automotive shipments. Automotives will continue to grow on higher North American auto production, which will boost steel production, consequently driving shipments in the Metals and Minerals category.
The company believes that improving operating efficiency along with growth in key markets will lead to mid single-digit carload growth in the coming quarters. The company also targets to maintain a modest operating ratio, given stronger volume growth at low incremental costs with productivity initiatives such as improving system velocity and fuel efficiency.
However, we were a bit disappointed with the company’s third quarter results. Earnings per share were in line with our expectation, but revenue failed to match the Zacks Consensus Estimate.
In the coming days, several headwinds such as competitive threats and uncertainties in the market condition of some of the product lines and downturn in the economy will likely limit the upside potential of the stock.
We see no earnings momentum for the stock over the last 30 days. The Zacks Consensus Estimates for the fourth quarter is currently pegged at $1.40 per share, reflecting a year-over-year increase of 8.60%.
Other Stock to Consider
Canadian Pacific Railway (CP - Analyst Report) is expected to perform impressively over the next few months based on volume additions, attractive tie-ups and healthy financial profile. It carries a Zacks #3 Rank (Hold rating).
Get the full Analyst Report on CNI - FREE
Get the full Analyst Report on CP - FREE